Will the global aging population become the leading longevity and anti-aging treatment market for gold?

Wen │ Philip, Cailene

As the global elderly population continues to grow, generations X, Y and the next generation have increased recognition of anti-aging products, as well as the increasing development of stem cell research and increasing demand for cell development, are driving the growth of the global longevity and anti-aging therapeutics market. With rising income levels and advancing anti-aging technologies, treatments are becoming more and more popular around the world. According to a research report by Esticast, it is estimated that the global longevity and anti-aging treatments market will grow at a compound annual growth rate of 13.9% until 2026.

Ageing rates in China will also continue to increase. According to China's most recent census data, the proportion of the elderly population (aged 65 and over) rose from 8.9% in 2010 to 13.5%. The working-age population (15-60 years old) fell nearly 7 percent to 63.4%. As the population ages gradually, the advantages of the labor force gradually weaken. In addition to increasing fertility, the existing labor force may be extended or even strengthened. In the past, it may be necessary to delay the retirement age in order to prolong the labor force. So helping older people stay healthy and stay young to cope with work is more important, and longevity and anti-aging treatments are a sneaky way out.

To meet the huge market and demand, Hoshong Group (00575) $REGENT PACIFIC (00575.HK)$It was also announced last week that the Chinese name was changed from the original Endurance Pacific to Shukang Group Co., Ltd., and the English name was changed from Regent Pacific to Endurance RP. The company said that the flagship group has begun to advance its health and longevity business, reflecting the company's future development plans and vision for the future of longevity, healthcare, health and life sciences.

Layout Tracking Aging Artificial Intelligence Gives a Look at the Long-Life Market

Xu Kang said that the development of this market is not without a hitch, and the layout of the market is about to begin. Already in December last year, Shukang completed the acquisition of Deep Longevity, a leading artificial intelligence company that tracks human aging processes and aims to extend reproductive life, and with its deployment of aging clock technology, the blue picture of the longevity market has improved. Deep Longevity earlier announced a partnership with LifeHub and LifeClinic, the largest healthcare and clinic in Hong Kong, to deploy a series of AI-driven ageing clocks to explore longevity prevention measures, including lifestyle choices and the effectiveness of pharmacotherapy.

THE BIOLOGICAL AGING CLOCK IS A NEW BIOMARKER THAT REFLECTS THE AGE OF HUMAN BEINGS, RATHER THAN ACTUAL AGE. These markers are often more predictive of mortality and can be used for early diagnosis, prevention, clinical trial management, and insurance applications of the disease. Deep Longevity, the original inventor of the deep aging clock, uses deep-learning biomarkers of aging, and has patented the technology.

The traditional methods of preventive medicine have focused on the use of early diagnosis of symptoms or reduction of disease risk in order to prevent disease. Alex Zhavoronkov, Chief Longevity Officer at Deep Longevity, pointed out that AI-led longevity medicine can reduce or even reverse physiological and psychological aging by focusing on multiple levels of human aging, recognizing longevity bottlenecks, and using the latest advances in science and technology. The artificial intelligence system developed by Deep Longevity can track the rate of aging at molecular, cellular, organismal, organ, system, physiological and psychological levels.

Precision medical software or a growth spurt

In addition to the longevity and anti-aging therapy markets, the global precision medicine software market demand has been increasing in recent years. According to a report by Global Industry Analysts, during the COVID-19 outbreak, the global precision medicine software market was estimated at $13 last year, and the post-overhaul size is expected to reach $26 million by 2027, compounded by 1 percent year-over-year growth. Of these, the U.S. precision medical software market was estimated at $3.521 last year, and China expects a market size of $5.378 by 2027, which is expected to surpass the United States.

Notably, Human Longevity, a global leader in the precision medical software market, aims to build a world-class database of healthy human genes, Human Longevity is a research strategic partner for Deep Longevity. Deep Longevity also provides a range of aging clocks for the network of Human Longevity physicians and researchers. This also means that precision medicine software is very likely to be its next benchmark, or even another growth point.

With the advancement of technology, human life expectancy will grow longer. The global service and demand for anti-aging and life-prolonging products will only continue to grow. The aging clock may also have a wider application in the future, including in clinical medicine, aging-reverse therapy, precision medicine, and even the insurance layer. The strength and opportunity it brings are worth looking forward to.

Analog drug or2023Sword of the Year at the Centennial Sword Market

While targeting the longevity and anti-aging markets, Fortacin, a brand-name biologic drug known as the “spray bottle” under Shushong, was approved by the National Drug Administration for the purpose of clinical trials to significantly increase the visibility of the drug in the future.

After the clinical trial was approved, Shukang has successfully acquired the Jiangsuwan Biochemical Pharmaceutical, under the auspices of the Star brand, paying a payment of US$320 million (about HK$2,496 million), which means that this year will clearly be available. SHUSHANG LAST WEEK FORECAST THAT THE DRUG IS EXPECTED TO BE LAUNCHED IN CHINA IN 2023, AND THE DRUG WILL HELP ABOUT 900 MILLION PATIENTS IN THE FIRST YEAR OF ITS INITIAL TARGET MARKET LAUNCH IN CHINA. According to medical studies, there are at least about 1 premature ejaculation in China.

In other words, Shushong Group initially focused only on less than 10% of its similar patients. Based on the average amount of 12 drugs per patient per year, the Chinese market for its initial target alone required 1.08 drugs, although Fortacin has not entered the pricing stage in China, but by importing original medicines and The average retail price of the national pharmaceutical product is around RMB 150, while Fortacin's initial Chinese market has the potential to reach RMB 162; and the entire PE competition is clearly market class.

The optimization of China's three-child policy this year has been widely publicized by many of the sectors and topics that have been promoted in the market. In the future, the demand for fertility enhancement will increase. This type of anti-premature release product, such as Fortacin, is in fact a major beneficiary. In addition, Deep Longevity leverages its invented deep aging clock technology to open up this aging-related longevity market opportunity to Shukhang Group.

82K Views